Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma

Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R(2)) has shown clinical synergy in front‐line and relapsed/refractory FL. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Hsiling, Trisal, Preeti, Bjorklund, Chad, Carrancio, Soraya, Toraño, Estela G., Guarinos, Carla, Papazoglou, Despoina, Hagner, Patrick R., Beldi‐Ferchiou, Asma, Tarte, Karin, Delfau‐Larue, Marie‐Hélène, Morschhauser, Franck, Ramsay, Alan G., Gandhi, Anita K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594227/
https://www.ncbi.nlm.nih.gov/pubmed/30767211
http://dx.doi.org/10.1111/bjh.15797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594227/
https://www.ncbi.nlm.nih.gov/pubmed/30767211
http://dx.doi.org/10.1111/bjh.15797

Ejemplares similares